Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 15;15(18):4593.
doi: 10.3390/cancers15184593.

Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case-Control Study

Rémy Ezzedine  1 , Anthony Canellas  2 , Charles Naltet  3 , Marie Wislez  4 , Reza Azarian  5 , Andrei Seferian  6 , Etienne Giroux Leprieur  1
Affiliations

Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case-Control Study

Rémy Ezzedine et al. Cancers (Basel). .

Abstract

The current first-line standard treatment for advanced small cell lung cancer (SCLC) is a combination of chemotherapy and immunotherapy. However, few efficacy data are available in a real-life settings, including frail patients. The aim of this study is to describe the real-life efficacy of chemoimmunotherapy in an unselected SCLC population. We conducted a retrospective multicenter study, which compared two cohorts of patients with treatment-naive metastatic SCLC treated in six academic centers in the Greater Paris area. Cohort 1 included patients treated with chemotherapy between January 2017 and December 2018, and cohort 2 included patients treated with chemoimmunotherapy between January 2019 and December 2020. A total of 153 consecutive patients were included (cohort 1: n = 96; cohort 2: n = 57). Clinical characteristics were similar between the two cohorts. Overall survival (OS) was statistically higher in cohort 2 (median survival 15.47 months) than in cohort 1 (median survival 9.5 months) (p = 0.0001). OS for patients with a performance status ≥2 and for patients ≥70 years old was not statistically different between the two cohorts. Chemoimmunotherapy efficacy was better compared to chemotherapy alone in case of brain or liver metastases. In conclusion, the combination of chemoimmunotherapy in metastatic SCLC appears to provide a real-life OS benefit. Dedicated clinical trials are needed to test this strategy in patients with impaired performance status or advanced age.

Keywords: atezolizumab; brain metastases; elderly; liver metastases; small-cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

EGL: honoraria and personal fees (advisory boards) from Roche. Other authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overall Survival in cohort 1 (chemotherapy) and cohort 2 (chemoimmunotherapy).
Figure 2
Figure 2
Progression-free survival in cohort 1 (chemotherapy) and cohort 2 (chemoimmunotherapy).
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J. Clin. 2023;73:17–48. doi: 10.3322/caac.21763. - DOI - PubMed
    1. Demedts I.K., Vermaelen K.Y., van Meerbeeck J.P. Treatment of extensive-stage small cell lung carcinoma: Current status and future prospects. Eur. Respir. J. 2010;35:202–215. doi: 10.1183/09031936.00105009. - DOI - PubMed
    1. Paz-Ares L., Chen Y., Reinmuth N., Hotta K., Trukhin D., Statsenko G., Hochmair M.J., Özgüroğlu M., Ji J.H., Garassino M.C., et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7:100408. doi: 10.1016/j.esmoop.2022.100408. - DOI - PMC - PubMed
    1. Calvert A.H., Newell D.R., Gumbrell L.A., O’Reilly S., Burnell M., Boxall F.E., Siddik Z.H., Judson I.R., Gore M.E., Wiltshaw E. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 1989;7:1748–1756. doi: 10.1200/JCO.1989.7.11.1748. - DOI - PubMed
    1. Rossi A., Di Maio M., Chiodini P., Rudd R.M., Okamoto H., Skarlos D.V., Früh M., Qian W., Tamura T., Samantas E., et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. J. Clin. Oncol. 2012;30:1692–1698. doi: 10.1200/JCO.2011.40.4905. - DOI - PubMed

LinkOut - more resources